Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05274243 · ClinicalTrials.gov registry record · Phase 2
2-HOBA Phase 2 Clinical Trial in Rheumatoid Arthritis
A Phase 2 study, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT05274243 is a Phase 2 study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 32 participants.
The verdict
NCT05274243, a Phase 2 study, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
This is a phase 2 study to determine 2-HOBA's tolerability, safety, and effect on isoLG-adducts in patients with rheumatoid arthritis (RA) patients. Up to 32 subjects will be randomized to 750mg 2-HOBA or matching placebo three times a day for 4 weeks. As primary outcome measures investigators will compare tolerability and adverse events and changes in isoLG adducts in active and placebo arms. Among prespecified exploratory outcomes investigators will compare changes in markers of inflammation, DAS28 score, and 24-hour blood pressure in active and placebo arms. This pilot study will inform the feasibility and design of future studies to examine the efficacy of 2-HOBA in RA patients.
Interventions
- OTHER Placebo
- DRUG 2-HOBA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2022-08-09 |
| Est. Completion | 2025-05-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05274243
The ClinicalTrials.gov registry entry for NCT05274243 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05274243 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05274243 about?
NCT05274243 is a clinical study titled "2-HOBA Phase 2 Clinical Trial in Rheumatoid Arthritis". This is a phase 2 study to determine 2-HOBA's tolerability, safety, and effect on isoLG-adducts in patients with rheumatoid arthritis (RA) patients. Up to 32 subjects will be randomized to 750mg 2-HOBA or matching placebo three times a day for 4 weeks. As primary outcome measures investigators will...
What is the current status of trial NCT05274243?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2022-08-09. Estimated completion is 2025-05-28.
What interventions are being tested in trial NCT05274243?
The interventions under investigation include: Placebo (OTHER), 2-HOBA (DRUG).
Who is sponsoring clinical trial NCT05274243?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.